Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and
effective in patients with advanced blood cancer. Patients must have already received
standard therapy. The study may last up to approximately 3 years.